WAYNE, Pa., July 15 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq: ESMC) today announced that Mark H. Karsch has been appointed Chief
Financial Officer effective July 18, 2005.
    Richard J. DePiano, Escalon's Chairman and CEO, commented, "I am pleased
that Mark has joined Escalon's executive management team. Mark's 27 years of
experience in finance, operations management and business planning, as well as
in developing new business ventures and strategic business partners, will help
us continue to achieve our business plan."
    Since August 2003, Mr. Karsch served as Chief Financial Officer of
Multimedia Marketing Training Solutions, a privately-held company. From 1991
to 2003, Mr. Karsch served as a Senior Vice President and Chief Financial
Officer for both private and publicly-traded companies.  Mr. Karsch is a
certified public accountant who began his career with Arthur Andersen, working
13 years with growth stage companies, both public and private.  Mr. Karsch
earned his BS in accounting from St. Joseph University.

    Founded in 1987, Escalon develops, markets and distributes ophthalmic
diagnostic, surgical and pharmaceutical products as well as vascular access
devices.  Drew, which operates as a separate division, provides
instrumentation and consumables for the diagnosis and monitoring of medical
disorders in the areas of diabetes, cardiovascular diseases and hematology, as
well as veterinary hematology and blood chemistry.  The Company seeks to
utilize strategic partnerships to help finance its development programs and is
also seeking acquisitions to further diversify its product line to achieve
critical mass in sales and take better advantage of the Company's distribution
capabilities.  Escalon has headquarters in Wayne, Pennsylvania and
manufacturing operations in Long Island, New York, New Berlin, Wisconsin,
Dallas, Texas, Oxford, Connecticut and Barrow-in-Furness, U.K.

    Note:  This press release contains statements that are considered
forward-looking under the Private Securities Litigation Reform Act of 1995,
including statements about the Company's future prospects.  They are based on
the Company's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially.  The
uncertainties and risks include whether the Company is able to improve upon
the operations of the Company's business units, including Drew, generate cash
and identify, finance, integrate operations of Drew and enter into business
relationships and acquisitions, uncertainties and risks related to new product
development, commercialization, manufacturing and market acceptance of new
products, marketing acceptance of existing products in new markets, the
continuity of royalty revenue, research and development activities, including
failure to demonstrate clinical efficacy, delays by regulatory authorities,
scientific and technical advances by the Company or third parties,
introduction of competitive products, third party reimbursement and physician
training as well as general economic conditions.  Further information about
these and other relevant risks and uncertainties may be found in the Company's
report on Form 10-K, and its other filings with the Securities and Exchange
Commission, all of which are available from the Commission as well as other
sources.

Link to this page: